Titre :

Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study

Auteur(s) :

Buisson, Anthony [Auteur]
Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte [M2iSH]
Infection Inflammation et Interaction Hôtes Pathogènes [CHU Clermont-Ferrand] [3IHP ]
Serrero, Mélanie [Auteur]
Hôpital Nord [CHU - APHM]
Orsat, Laurie [Auteur]
Infection Inflammation et Interaction Hôtes Pathogènes [CHU Clermont-Ferrand] [3IHP ]
Nancey, Stéphane [Auteur]
Centre International de Recherche en Infectiologie [CIRI]
Riviere, Pauline [Auteur]
Université de Bordeaux [UB]
Altwegg, Romain [Auteur]
Hôpital Saint Eloi [CHU Montpellier]
Peyrin-Biroulet, Laurent [Auteur]
Nutrition-Génétique et Exposition aux Risques Environnementaux [NGERE]
Nachury, Maria [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Hebuterne, Xavier [Auteur]
Université Côte d'Azur [UniCA]
Gilletta, Cyrielle [Auteur]
Centre Hospitalier Universitaire de Toulouse [CHU Toulouse]
Flamant, Mathurin [Auteur]
Viennot, Stéphanie [Auteur]
Bouguen, Guillaume [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Amiot, Aurélien [Auteur]
Groupe Henri Mondor-Albert Chenevier
Mathieu, Stéphane [Auteur]
Vuitton, Lucine [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Plastaras, Laurianne [Auteur]
CH Colmar
Bourreille, Arnaud [Auteur]
Centre Hospitalier Universitaire de Nantes = Nantes University Hospital [CHU Nantes]
Caillo, Ludovic [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Goutorbe, Felix [Auteur]
Centre Hospitalier de la Côte Basque [CHCB]
De Chambrun, Guillaume Pineton [Auteur]
Attar, Alain [Auteur]
Roblin, Xavier [Auteur]
Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] [CHU ST-E]
Pereira, Bruno [Auteur]
CHU Clermont-Ferrand
Fumery, Mathurin [Auteur]
Université de Picardie Jules Verne [UPJV]

Titre de la revue :

Inflammatory Bowel Diseases

Nom court de la revue :

Inflamm. Bowel Dis.

Numéro :

29

Pagination :

579–588

Date de publication :

2022-07-19

ISSN :

1078-0998

Mot(s)-clé(s) en anglais :

Crohn's disease
ulcerative colitis
biologics
small molecules
acceptability

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Background Owing to growing number of therapeutic options with similar efficacy and safety, we compared the acceptability of therapeutic maintenance regimens in inflammatory bowel disease (IBD). Methods From a ...
Lire la suite >Background Owing to growing number of therapeutic options with similar efficacy and safety, we compared the acceptability of therapeutic maintenance regimens in inflammatory bowel disease (IBD). Methods From a nationwide study (24 public or private centers), IBD patients were consecutively included for 6 weeks. A dedicated questionnaire including acceptability numerical scales (ANS) ranging from 0 to 10 (highest acceptability) was administered to both patients and related physicians. Results Among 1850 included patients (65.9% with Crohn’s disease), the ANS were 8.68 ± 2.52 for oral route (first choice in 65.8%), 7.67 ± 2.94 for subcutaneous injections (first choice in 21.4%), and 6.79 ± 3.31 for intravenous infusions (first choice in 12.8%; P < .001 for each comparison). In biologic-naïve patients (n = 315), the most accepted maintenance regimens were oral intake once (ANS = 8.8 ± 2.2) or twice (ANS = 6.9 ± 3.4) daily and subcutaneous injections every 12 or 8 weeks (ANS = 7.9 ± 3.0 and ANS = 7.2 ± 3.2, respectively). Among 342 patients with prior exposure to subcutaneous biologics, the preferred regimens were subcutaneous injections (≥2 week-intervals; ANS between 9.1 ± 2.3 and 8.1 ± 2.7) and oral intake once daily (ANS = 7.7 ± 3.2); although it was subcutaneous injections every 12 or 8 weeks (ANS = 8.4 ± 3.0 and ANS = 8.1 ± 3.0, respectively) and oral intake once daily (ANS = 7.6 ± 3.1) in case of prior exposure to intravenous biologics (n = 1181). The impact of usual therapeutic escalation or de-escalation was mild (effect size <0.5). From patients’ acceptability perspective, superiority and noninferiority cutoff values should be 15% and 5%, respectively. Conclusions Although oral intake is overall preferred, acceptability is highly impacted by the rhythm of administration and prior medication exposures. However, SC treatment with long intervals between 2 injections (≥8 weeks) and oral intake once daily seems to be the most accepted modalities.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T01:05:31Z
2024-03-15T10:26:01Z